Pomalidomide
Brand name: Pomalyst
Rank #31 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$589.0M
Total Cost
27,253
Total Claims
$589.0M
Total Cost
1,082
Prescribers
$22K
Cost per Claim
1,779
Beneficiaries
27,261
30-Day Fills
$544K
Avg Cost/Provider
25
Avg Claims/Provider
Share of Medicare Part D Spending
0.21%
of total Medicare Part D spending
$589.0M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $589.0M total
🔎 Data Overview
Ranked #31 out of 500 drugs tracked by total cost. Pomalidomide represents a significant portion of Medicare drug spending.
At $21,612 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $544,349 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $331,077 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Pomalidomide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Suzan Rosen | Nurse Practitioner | Miami, FL | 249 | $5.6M |
| 2 | Catharine Skoog | Physician Assistant | Milwaukee, WI | 217 | $4.9M |
| 3 | Jonathan Kaufman | Hematology-Oncology | Atlanta, GA | 169 | $3.8M |
| 4 | Harsh Parmar | Medical Oncology | Hackensack, NJ | 178 | $3.6M |
| 5 | Jason Valent | Hematology-Oncology | Strongsville, OH | 157 | $3.4M |
| 6 | Emerentia Agyemang | Nurse Practitioner | Boston, MA | 146 | $3.2M |
| 7 | Larry Anderson | Hematopoietic Cell Transplantation and Cellular Therapy | Dallas, TX | 161 | $3.1M |
| 8 | Ami Ndiaye | Nurse Practitioner | Charlotte, NC | 137 | $3.1M |
| 9 | Frances Bell | Nurse Practitioner | New York, NY | 138 | $2.9M |
| 10 | Zachary Hruska | Nurse Practitioner | Charlottesville, VA | 133 | $2.8M |
| 11 | Ravi Vij | Medical Oncology | Saint Louis, MO | 126 | $2.7M |
| 12 | Jose Sarriera | Hematology-Oncology | Orlando, FL | 118 | $2.6M |
| 13 | Pooja Phull | Hematology-Oncology | Hackensack, NJ | 133 | $2.5M |
| 14 | Isabel Concepcion | Nurse Practitioner | Nashville, TN | 104 | $2.3M |
| 15 | John Winters | Hematology-Oncology | Scarborough, ME | 93 | $2.1M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology